t-butyl 4-[(3,5-difluoropyridin-2-yl)oxy]piperidine-1-carboxylate | 944390-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: t-butyl 4-[(3,5-difluoropyridin-2-yl)oxy]piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(3,5-difluoropyridin-2-yl)oxypiperidine-1-carboxylate
• CAS: 944390-88-9
• 化学式: C₁₅H₂₀F₂N₂O₃
• 分子量: 314.332
• InChiKey: VSRYSVACJDNTHB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,3,5-三氟吡啶 、 N-Boc-4-羟基哌啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以38%的产率得到t-butyl 4-[(3,5-difluoropyridin-2-yl)oxy]piperidine-1-carboxylate
  参考文献：
  名称：

  EP2258697

  摘要：

  公开号：

文献信息

• [EN] HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYLOXYHÉTÉROCYCLYLE CONVENANT COMME INHIBITEURS DE LA PDE10
  申请人：AMGEN INC

  公开号：WO2011143495A1

  公开（公告）日：2011-11-17

  Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.

  杂芳基氧杂环基化合物，以及含有它们的组合物，以及制备这类化合物的方法。本文还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、亨廷顿病、双相情感障碍、强迫症等。
• HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE
  申请人：Motoki Kayoko

  公开号：US20110053933A1

  公开（公告）日：2011-03-03

  The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R 1 and R 2 independently represents a group such as a hydrogen atom or a halogen atom; R 3 represents a group such as a hydrogen atom; each of R 4 and R 5 independently represents a group such as a hydrogen atom, a halogen atom or a C 1-4 alkyl group; each of R 6 and R 7 independently represents a hydrogen atom or a C 1-4 alkyl group; X represents a group such as a C 3-10 cycloalkyl group, C 6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as —CO—, —O— or —NRa—, and Ra represents a group such as a hydrogen atom or a C 1-4 alkyl group.

  本发明提供了一种新型的羟基喹喔啉羧酰胺衍生物，可用于预防和/或治疗血液凝固障碍。该化合物由式(i)表示，或其药学上可接受的盐：其中，R1和R2各自独立地表示氢原子或卤素原子等基团；R3表示氢原子等基团；R4和R5各自独立地表示氢原子、卤素原子或C1-4烷基等基团；R6和R7各自独立地表示氢原子或C1-4烷基等基团；X表示C3-10环烷基、C6-10芳基或5-至10元杂环基等基团，该基团可以被选自取代基团α的取代基团所取代；Y表示—CO—、—O—或—NRa—等基团，其中Ra表示氢原子或C1-4烷基等基团。
• OGA INHIBITOR COMPOUNDS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210122763A1

  公开（公告）日：2021-04-29

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
• US8497265B2
  申请人：——

  公开号：US8497265B2

  公开（公告）日：2013-07-30
• US9376450B2
  申请人：——

  公开号：US9376450B2

  公开（公告）日：2016-06-28